Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD

Inclusion Criteria:

1. Age 6 to 17 years inclusive at the time of consent/assent. The date of signature of
the informed consent/assent is defined as the beginning of the Screening Period. This
inclusion criterion will only be assessed at the first screening visit.

2. Male, or non-pregnant, non-lactating female who agrees to comply with any applicable
contraceptive requirements of the protocol or females of non-childbearing potential.

3. Subject meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-V) criteria for a primary diagnosis of ADHD based on an accepted ADHD diagnostic
instrument and documented in the subject's medical record. Subject's ADHD is
currently adequately controlled with an amphetamine-based product.

4. Subject is functioning at an age appropriate level intellectually, as determined by
the investigator.

5. Must be considered "healthy". Healthy status is defined by absence of evidence of any
active or chronic disease other than their ADHD following a detailed medical and
surgical history, a complete physical examination including vital signs, 12-lead ECG,
hematology, blood chemistry, and urinalysis.

6. Ability to swallow a capsule of investigational product whole.

Exclusion Criteria:

1. Current use of any ADHD medication other than an amphetamine-based product.

2. History of any hematological, hepatic, respiratory, cardiovascular, renal,
neurological or psychiatric disease, gall bladder removal, or current or recurrent
disease other than their ADHD

3. Current or relevant history of physical or psychiatric illness, any medical disorder
that may require treatment

4. Subject has a current, controlled or uncontrolled, comorbid psychiatric diagnosis
with significant symptoms

5. Subject meets DSM-V diagnosis of conduct disorder.

6. Subject is considered a suicide risk in the opinion of the investigator, has
previously made a suicide attempt, or is currently demonstrating active suicidal
ideation.

7. Subject is underweight based on Centers for Disease Control and Prevention (CDC) body
mass index (BMI)- for-age sex-specific values

8. Subject is significantly overweight based on CDC BMI-for-age sex specific values

9. Subject has a known history of symptomatic cardiovascular disease, advanced
arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart
rhythm abnormalities, coronary artery disease, or other serious cardiac problems

10. Subject has a concurrent chronic or acute illness, disability, or other condition
that might confound the results of safety assessments conducted in the study

11. Subject has a history of seizure, a chronic or current tic disorder, or a current
diagnosis of Tourette's Disorder. Subject has a history of tics that are judged to be
exclusionary.

12. Subject's blood pressure measurements exceed the 90th percentile for age, sex, and
height

13. Subject has a known history of hypertension.

14. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.

15. Subject has any clinically significant ECG or clinically significant laboratory
abnormality

16. Subject has abnormal thyroid function

17. Known or suspected intolerance or hypersensitivity to the investigational product(s),
closely-related compounds, or any ingredients.

18. History of alcohol or other substance abuse within the last year. Subjects with a
lifetime history of amphetamine, cocaine, or other stimulant abuse and/or dependence
will be excluded.

19. Use Within 30 days prior to the first dose of investigational product:

- have used an investigational product

- have been enrolled in a clinical study (including vaccine)

- have had any substantial changes in eating habits

20. A positive screen for alcohol or drugs of abuse. A positive hepatitis B surface
antigen (HBsAg); hepatitis C virus (HCV); or HIV antibody screen.

21. Use of tobacco in any form in the last 30 days

22. Prior screen failure, enrollment, or participation in this study.